3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
17
Neoplasm Metastasis
9
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
3
Melanoma
3
Brain Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Neuroblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Colorectal Neoplasms
2
Advanced Cancer
2
Urologic Neoplasms
1
Unilateral Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Multiple Myeloma
1
Interventions
Cisplatin
45
Radiotherapy
32
Fluorouracil
27
Paclitaxel
26
Irinotecan
17
Docetaxel
16
Oxaliplatin
11
Carboplatin
10
pembrolizumab
9
Cetuximab
8
tislelizumab
7
Surgical Procedures, Operative
7
Neoadjuvant Therapy
7
Drug Therapy
7
Radiation
6
Leucovorin
6
sintilimab
5
Nivolumab
5
Immunohistochemistry
5
Chemotherapy, Adjuvant
5
Capecitabine
5
nedaplatin
3
durvalumab
3
camrelizumab
3
S 1 (combination)
3
Magnetic Resonance Spectroscopy
3
Gene Expression Profiling
3
Gemcitabine
3
Fluorodeoxyglucose F18
3
Erlotinib Hydrochloride
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Esophageal Squamous Cell Carcinoma
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled